:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Authors:	Stefano Siboni, Marco Sozzi, C. Prakash Gyawali
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	https://onlinelibrary.wiley.com/doi/10.1111/apt.70413
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease. Authors' Reply
by: Stefano Siboni, et al.
Published: (2026)

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease. Authors' Reply
by: Walter W. Chan, et al.
Published: (2026)

Editorial: Do we Need to Adapt GERD Metrics Based on the Population Being Evaluated? Authors' Reply
by: Walter W. Chan, et al.
Published: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
by: Yu‐Sheng Lin, et al.
Published: (2026)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
by: Elisa Pinto, et al.
Published: (2026)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
by: Yewan Park, et al.
Published: (2024)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease
by: Javier Chahuán, et al.
Published: (2026)

Letter: Enhancing HCC Surveillance: GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety—Authors' Reply
by: Gamal Shiha, et al.
Published: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
by: Ryan Yanzhe Lim, et al.
Published: (2026)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
by: Sofia Tsitsou, et al.
Published: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
by: A. B. Fons, et al.
Published: (2026)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
by: Lucie Simonis, et al.
Published: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
by: Shintaro Akiyama, et al.
Published: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
by: J. M. Schattenberg, et al.
Published: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
by: Virginia Solitano, et al.
Published: (2024)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
by: Irene Spinelli, et al.
Published: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
by: Nathan Grellier, et al.
Published: (2025)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
by: Bernardo de Faria Moraes, et al.
Published: (2026)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
by: Nina Dominik, et al.
Published: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
by: Mohamed El‐Kassas, et al.
Published: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
by: Jeffrey D. McCurdy, et al.
Published: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
by: Yu‐Sheng Lin, et al.
Published: (2026)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
by: Hong‐Li Liu, et al.
Published: (2026)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
by: Yu‐Sheng Lin, et al.
Published: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
by: Yuki Utakata, et al.
Published: (2026)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
by: Teresa Seum, et al.
Published: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
by: Lesley A. Patmore, et al.
Published: (2025)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
by: Pinelopi Arvaniti, et al.
Published: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
by: Alberto Ferrarese, et al.
Published: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
by: Lukas Burghart, et al.
Published: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
by: Chachrit Khunsriraksakul, et al.
Published: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
by: Juan Macias, et al.
Published: (2025)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
by: Kuo‐Cheng Wu, et al.
Published: (2024)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
by: Luis Antonio Díaz, et al.
Published: (2025)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
by: Ankit Kumar, et al.
Published: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
by: Isabel Carbery, et al.
Published: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
by: Christian Labenz, et al.
Published: (2026)